event-trade登录编辑
财联社电报Qwen · 实盘不做把握 4/10不做原因:证据不足
北京时间·🕒 发布 19:01:35·⟳ 抓取 19:03:00 +1m25s·⚡ 决策 08-28 21:25:03 +2h22m·60.4 天前

云南白药2026年半年度净利润37.01亿元同比仅增1.88%，Q2环比下滑18%并披露中期分红

This earnings report is a mixed signal of 'low growth on the surface + Q2 sequential decline + dividend announcement'. The headline YoY +1.88% itself cannot determine whether it beat, met, or missed consensus expectations. Q2 net profit dropped 18% QoQ, but the seasonal pattern has not been verified. Furthermore, the segment breakdown and management outlook have not been read. There is no clear strong catalyst in either direction. Neither long nor short has positive expected value, so AVOID.

📄 原文财联社电报↗ 原文
云南白药：上半年净利润37.01亿元 同比增长1.88%
【云南白药：上半年净利润37.01亿元 同比增长1.88%】财联社8月28日电，云南白药(000538.SZ)公告称，公司发布2026年半年度报告，实现营业收入218.84亿元，同比增长2.95%；归属于上市公司股东的净利润37.01亿元…
不做 云南白药（000538.SZ）
Half-year report shows low growth (net profit +1.88%) + Q2 sequential decline of 18%, but comparison with market expectations is unknown, segment breakdown and decline reason are missing, and the direction cannot be determined; the positiv…
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)

研究档案

结论摘要

Yunnan Baiyao's H1 report shows revenue of 21.884 billion yuan (+2.95%), net profit of 3.701 billion yuan (+1.88%), and Q2 single-quarter net profit of 1.664 billion yuan (QoQ -18%), with a mid-term dividend of 10.38 yuan per 10 shares announced simultaneously. Superficially it is low growth + sequential decline, but whether it met/missed/below market expectations cannot be determined without consensus data; the cause of the Q2 sequential decline has not been disclosed, and the sustainability of the decline cannot be assessed; the dividend is positive but has limited elasticity relative to mar

🔎 新鲜度:最早出现 2026-08-28 · 扩散 low · price-in 风险 medium ↗

关键理由

  • Low growth in the half-year report + Q2 sequential decline are already clear facts, but whether they missed expectations is unknown; the direction cannot be determined
  • Mid-term dividend of 10.38 yuan per 10 shares provides some positive support, but elasticity relative to market cap is limited
  • Segment breakdown, Q2 decline reason, and management outlook are all missing; the evidence chain is incomplete

主要风险

  • If Q2 sequential decline is caused by structural deterioration in health products or pharmaceutical distribution, subsequent quarters may continue to be sluggish, forming sustained pressure
  • If the market originally had higher expectations for the half-year report, low growth may trigger expectations revision

反向证据

  • 做多前查反向 · 来源 web · 影响 none
    No consensus forecast data for H1 2026 was found; cannot confirm whether it met or missed expectations
    检索:Yunnan Baiyao 2026 semi-annual report market expectations consensus forecast
  • 做空前查反向 · 来源 web · 影响 none
    The specific reason for the Q2 sequential decline was not found; cannot confirm whether it is structural deterioration or seasonal fluctuation
    检索:Yunnan Baiyao Q2 sequential decline reason health products pharmaceutical distribution

先例如何影响了这次决策

对本次决策的影响:No precedent support; cannot calibrate target price/stop-loss based on similar events; judgment is based only on fundamentals and direction ambiguity

方向:No available historical precedents

涨幅量级:Not enough samples to calibrate the magnitude

形态:No basis for judging sell-on-news

原文全文

展开原文 · 202 字
【云南白药：上半年净利润37.01亿元 同比增长1.88%】财联社8月28日电，云南白药(000538.SZ)公告称，公司发布2026年半年度报告，实现营业收入218.84亿元，同比增长2.95%；归属于上市公司股东的净利润37.01亿元，同比增长1.88%。公司拟每10股派发现金红利10.38元(含税)。小财注：公司Q2净利润16.64亿，Q1净利润20.37亿，据此计算，Q2净利润环比下降18%。

决策记录链 · 只追加

每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。

这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。